TABLE 2.
H. pylori eradication rates of each therapy group and eradication rates according to each treatment regimen and antimicrobial susceptibility.
| Culture‐based tailored therapy | Empirical concomitant therapy | p value | ||
|---|---|---|---|---|
| Intention‐to‐treat | 84.2% (197/234) | 83.3% (65/78) | 0.859 | |
| 95% CI | 79.1%–88.4% | 73.9%–90.3% | ||
| Per‐protocol | 92.9% (197/212) | 91.5% (65/71) | 0.702 | |
| 95% CI | 88.9%–95.8% | 83.4%–96.4% | ||
| Resistance pattern (Per‐protocol) | ||||
| Clarithromycin | metronidazole | |||
| Susceptible | susceptible | 94.5% (120/127; PAC) | 97.5% (39/40; PACM) | 0.681 |
| Susceptible | resistant | 86.7% (26/30; PAC) | 100% (14/14; PACM) | 0.290 |
| Resistant | susceptible | 92.1% (35/38; PAM) | 90.9% (10/11; PACM) | 1.000 |
| Resistant | resistant | 94.1% (16/17; PBTM) | 33.3% (2/6; PACM) | 0.008 |
Abbreviations: CI, confidence interval; PAC, lansoprazole, amoxicillin, and clarithromycin; PACM, lansoprazole, amoxicillin, clarithromycin, and metronidazole; PAM, lansoprazole, amoxicillin, and metronidazole; PBTM, lansoprazole, bismuth potassium citrate, tetracycline and metronidazole.